Business
Bloomios Completes $23.5 Million Acquisition of Leading Gummy Manufacturer
Bloomios Completes $23.5 Million Acquisition of Leading Gummy Manufacturer.
About this update from Bloomios Inc.
[{"type":"text","content":"\n\n\n\nBloomios Completes $23.5 Million Acquisition of Leading Gummy Manufacturer\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n\n\n\n\n\n\nBloomios Completes $23.5 Million Acquisition of Leading Gummy Manufacturer\nPR Newswire\nSANTA BARBARA, Calif., Oct. 27, 2022\n\n\n\nTransaction Expected to Double Production Capacity and Supports Entry of Direct-to-Consumer Market\nSANTA BARBARA, Calif., Oct. 27, 2022 /PRNewswire/ -- Bloomios, Inc. (the \"Company\") (OTCQB: BLMS), a leading white-label and private-label manufacturer and wholesaler of hemp-derived nutraceutical, cosmetics and pet products, has acquired Infusionz, a wholly-owned subsidiary of Upexi (NASDAQ: UPXI).\n\n \n \n \n \n \n \n\n \n\"This acquisition is highly accretive and we believe that it will position Bloomios to uplist to Nasdaq,\"Through this transaction, Upexi and Bloomios have forged a long-term partnership. Moving forward, Bloomios will manufacture products retained by Upexi and Upexi has provided significant financing to enable this transaction.\nThe acquisition includes Infusionz's portfolio of CBD gummy brands and customers, along with its associated order flow, product formulations, manufacturing operations, equipment and sales team. \nThe total purchase consideration of approximately $23.5 million consisted of cash consideration of $5.5 million and $18 million of non-cash consideration. The non-cash consideration consisted of the issuance by Bloomios to Upexi of a $4.5 million senior secured convertible debenture, a $5 million secured subordinated promissory note, and shares of a newly created Series D Convertible Preferred Stock with a value of $8.5 million.\nThe added operations are expected to more than double Bloomios's current production capacity across key production lines while reducing redundant costs across both the acquired and existing operations. The acquisition will contribute in excess of $22 million in annualized gross revenue.\n\"This acquisition is highly accretive and we believe that it will position Bloomios to uplist to Nasdaq,\" said Ba...